Evangelia Stamou

This study shows that WNT signaling enhances NF-κB activation and drug resistance in KRAS-mutant colorectal cancer, suggesting a therapeutic strategy targeting WNT and MEK pathways.

The paper identifies glucuronidation pathway upregulation as a mechanism by which colon cancer cells develop resistance to trametinib, showing that inhibiting this pathway can reverse resistance in both Drosophila and mouse models.